Grant: Discovery Grants Program - Individual
University of Calgary
$40,000.00
High-throughput stem cell bioprocess design - environmental influences on pluripotent stem cell expansion and differentiation
EF 2011-12
Résumé
Regenerative medicine is a rapidly growing billion dollar multidisciplinary field at the intersection of medicine, engineering and science. It aims to create living, functional tissues that can repair or replace damaged, diseased or aging tissues or organs. Stem cells are critical to the success of regenerative medicine therapies, and what are needed are technologies to bridge the gap between basic biology and the clinical application of stem cells. The proposed research program will accelerate the development of these technologies, specifically targeting a reliable, reproducible way to grow stem cells to build tissues. The research will focus on pluripotent stem cells as they have the potential to generate any cell type in the body, i.e. large numbers of specialized (differentiated) cells. They can be derived from the inner cell mass of an early development blastocyst (embryonic stem cells) or from adult cells such as skin cells that are modified by the addition of key factors to be pluripotent (induced pluripotent stem cells). One of the major stumbling blocks on the road to effective regenerative medicine treatments is the limited number of available donor cells, and the small-scale, labour-intensive methods for culturing and differentiating them. The primary objective of the proposed research is to develop engineering methods and technology for efficiently growing human pluripotent stem cells in computer-controlled bioreactors. First, the effect of key bioreactor conditions (such as oxygen level) and the transport of nutrients will be examined for individual stem cell clusters and entire bioreactors. Second, new technology will be developed to accelerate the development of bioprocesses through the use of multiple smaller bioreactors as high-throughput tools to study many conditions quickly. The long term outcomes include innovative bioprocess designs, as well as critical knowledge of how output parameters (i.e. cell type, behaviour) are influenced by cell processing parameters (i.e. bioreactor oxygen level). This is fundamentally necessary for the regulatory approval and clinical application of stem cell technologies, including the generation and transplantation of cells/tissues for the treatment of human ailments (i.e. stroke, Parkinson's disease, diabetes).
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
239083-2011
Name nom
Kallos, Michael
Department département
Chemical and Petroleum Engineering
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
40000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
5
Application title
High-throughput stem cell bioprocess design - environmental influences on pluripotent stem cell expansion and differentiation
Keyword
NSERC
Application summary
Regenerative medicine is a rapidly growing billion dollar multidisciplinary field at the intersection of medicine, engineering and science. It aims to create living, functional tissues that can repair or replace damaged, diseased or aging tissues or organs. Stem cells are critical to the success of regenerative medicine therapies, and what are needed are technologies to bridge the gap between basic biology and the clinical application of stem cells. The proposed research program will accelerate the development of these technologies, specifically targeting a reliable, reproducible way to grow stem cells to build tissues. The research will focus on pluripotent stem cells as they have the potential to generate any cell type in the body, i.e. large numbers of specialized (differentiated) cells. They can be derived from the inner cell mass of an early development blastocyst (embryonic stem cells) or from adult cells such as skin cells that are modified by the addition of key factors to be pluripotent (induced pluripotent stem cells). One of the major stumbling blocks on the road to effective regenerative medicine treatments is the limited number of available donor cells, and the small-scale, labour-intensive methods for culturing and differentiating them. The primary objective of the proposed research is to develop engineering methods and technology for efficiently growing human pluripotent stem cells in computer-controlled bioreactors. First, the effect of key bioreactor conditions (such as oxygen level) and the transport of nutrients will be examined for individual stem cell clusters and entire bioreactors. Second, new technology will be developed to accelerate the development of bioprocesses through the use of multiple smaller bioreactors as high-throughput tools to study many conditions quickly. The long term outcomes include innovative bioprocess designs, as well as critical knowledge of how output parameters (i.e. cell type, behaviour) are influenced by cell processing parameters (i.e. bioreactor oxygen level). This is fundamentally necessary for the regulatory approval and clinical application of stem cell technologies, including the generation and transplantation of cells/tissues for the treatment of human ailments (i.e. stroke, Parkinson's disease, diabetes).